Close Menu

NEW YORK – In secondary analysis of data from the TAILORx trial, researchers have added new confirming evidence that patients with high risk scores from Genomic Health's Oncotype DX appear to benefit significantly from added chemotherapy.

Investigators led by the trial's PI Joseph Sparano shared their findings in JAMA Oncology today and also presented the analysis at the European Society for Medical Oncology 2019 Congress.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.